A recommended scale for cognitive screening in clinical trials of Parkinson's disease |
| |
| Authors: | Kelvin L. Chou,Melissa M. Amick,Jason Brandt,Richard Camicioli,Karen Frei,Darren Gitelman,Jennifer Goldman,John Growdon,Howard I. Hurtig,Bonnie Levin,Irene Litvan,Laura Marsh,Tanya Simuni,Alexander I. Tr ster,Ergun Y. Uc |
| |
| Affiliation: | 1. Departments of Neurology and Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA;2. VA Boston Healthcare System and Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA;3. Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;4. Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada;5. The Parkinson's and Movement Disorders Institute, Fountain Valley, California, USA;6. Departments of Neurology and Radiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA;7. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA;8. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA;9. Depratment of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA;10. Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA;11. Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA;12. Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA;13. Parkinson's Disease and Movement Disorders Center and Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA;14. Department of Neurology, University of North Carolina‐Chapel Hill, Chapel Hill, North Carolina, USA;15. Department of Neurology, University of Iowa, Iowa City, Iowa, USA;16. Veterans Affairs Medical Center, Iowa City, Iowa, USA |
| |
| Abstract: | Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society |
| |
| Keywords: | Parkinson's disease cognitive impairment cognitive screening |
|
|
